ARS Pharmaceuticals(SPRY)
$3.95+0.38 (+10.64%)
SPRY
ARS Pharmaceuticals financials statements
$3.95
At close:+0.38 (+10.64%)
Want to see SPRY full AI Analyst Report?
ARS Pharmaceuticals (SPRY) Ratios
593 Followers
ARS Pharmaceuticals Ratios
SPRY's free cash flow for Q3 2026 was $-33.71M. For the 2026 fiscal year, SPRY's free cash flow was increased by $0.00 and operating cash flow was $-33.71M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.28 | 14.26 | 96.85 | 51.01 | 7.42 |
| Quick Ratio | 7.06 | 14.04 | 96.85 | 51.01 | 7.42 |
| Cash Ratio | 1.06 | 2.17 | 29.68 | 38.67 | 7.34 |
| Solvency Ratio | -0.80 | 0.09 | -22.36 | -4.02 | -0.22 |
| Operating Cash Flow Ratio | -4.36 | 0.58 | -24.79 | -7.36 | -2.14 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -250.07 | 0.00 | -5.05 |
| Net Current Asset Value | $ 71.50M | $ 239.94M | $ 229.13M | $ 269.15M | $ -31.98M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.29 | 0.00 | 0.00 | 0.00 | 0.15 |
| Debt-to-Equity Ratio | 0.84 | 0.00 | 0.00 | 0.00 | -0.29 |
| Debt-to-Capital Ratio | 0.46 | 0.00 | 0.00 | 0.00 | -0.41 |
| Long-Term Debt-to-Capital Ratio | 0.46 | 0.00 | 0.00 | 0.00 | -0.19 |
| Financial Leverage Ratio | 2.87 | 1.37 | 1.01 | 1.03 | -1.97 |
| Debt Service Coverage Ratio | -64.38 | 0.00 | -284.59 | 0.00 | -5.37 |
| Interest Coverage Ratio | -69.05 | 0.00 | 0.00 | 0.00 | -183.53 |
| Debt to Market Cap | 0.08 | 0.00 | 0.00 | 0.00 | 0.04 |
| Interest Debt Per Share | 1.00 | 0.00 | 0.00 | 0.01 | 0.32 |
| Net Debt to EBITDA | -0.33 | -6.07 | 1.05 | 5.97 | 2.65 |
| Profitability Margins | |||||
| Gross Profit Margin | 75.77% | 76.94% | 100.00% | 100.00% | 96.13% |
| EBIT Margin | -200.26% | 9.29% | -225066.67% | -2698.78% | -353.32% |
| EBITDA Margin | -198.64% | 9.38% | -224823.33% | -2674.54% | -349.46% |
| Operating Profit Margin | -212.92% | -3.46% | -225066.67% | -2698.78% | -353.32% |
| Pretax Profit Margin | -203.35% | 9.29% | -181216.67% | -2635.41% | -367.65% |
| Net Profit Margin | -203.25% | 8.97% | -181216.67% | -2635.41% | -367.65% |
| Continuous Operations Profit Margin | -203.25% | 8.97% | -181216.67% | -2635.41% | -367.65% |
| Net Income Per EBT | 99.95% | 96.52% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 95.50% | -268.76% | 80.52% | 97.65% | 104.06% |
| Return on Assets (ROA) | -52.28% | 2.28% | -23.31% | -12.32% | -32.94% |
| Return on Equity (ROE) | -149.92% | 3.11% | -23.56% | -12.71% | 64.74% |
| Return on Capital Employed (ROCE) | -62.20% | -0.94% | -29.26% | -12.87% | -36.53% |
| Return on Invested Capital (ROIC) | -62.17% | -0.91% | -29.23% | -12.86% | -34.20% |
| Return on Tangible Assets | -54.69% | 2.33% | -23.31% | -12.32% | -32.94% |
| Earnings Yield | -14.92% | 0.78% | -10.42% | -10.18% | -10.53% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.20 | 9.73 | 0.04 | 0.00 | 5506.00 |
| Payables Turnover | 3.57 | 2.08 | 0.00 | 0.00 | 0.12 |
| Inventory Turnover | 2.44 | 3.94 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 34.19 | 83.63 | 0.04 | 1.70 | 7.95 |
| Asset Turnover | 0.26 | 0.25 | 0.00 | 0.00 | 0.09 |
| Working Capital Turnover Ratio | 0.30 | 0.33 | 0.00 | 0.01 | 0.16 |
| Cash Conversion Cycle | 161.36 | -45.19 | 9672.50 | 0.00 | -3060.45 |
| Days of Sales Outstanding | 114.11 | 37.51 | 9672.50 | 0.00 | 0.07 |
| Days of Inventory Outstanding | 149.57 | 92.54 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 102.32 | 175.25 | 0.00 | 0.00 | 3060.52 |
| Operating Cycle | 263.68 | 130.05 | 9672.50 | 0.00 | 0.07 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.73 | 0.14 | -0.62 | -1.00 | -0.61 |
| Free Cash Flow Per Share | -1.74 | 0.13 | -0.62 | -1.01 | -0.61 |
| Dividend Paid and CapEx Coverage Ratio | -504.03 | 24.06 | -338.66 | -201.40 | -319.29 |
| Capital Expenditure Coverage Ratio | -504.03 | 24.06 | -338.66 | -201.40 | -319.29 |
| Operating Cash Flow Coverage Ratio | -1.77 | 322.57 | -216.30 | -83.32 | -1.94 |
| Operating Cash Flow to Sales Ratio | -2.03 | 0.15 | -1975.53 | -30.45 | -3.19 |
| Free Cash Flow Yield | -14.91% | 1.27% | -11.39% | -11.82% | -9.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.70 | 127.88 | -9.60 | -9.83 | -9.50 |
| Price-to-Sales (P/S) Ratio | 13.63 | 11.47 | 17392.67 | 258.99 | 34.92 |
| Price-to-Book (P/B) Ratio | 10.05 | 3.98 | 2.26 | 1.25 | -6.15 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.71 | 78.76 | -8.78 | -8.46 | -10.92 |
| Price-to-Operating Cash Flow Ratio | -6.72 | 75.49 | -8.80 | -8.50 | -10.95 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -1.12 | 0.28 | -0.40 | -0.00 |
| Enterprise Value Multiple | -7.19 | 116.19 | -6.69 | -3.72 | -7.34 |
| Enterprise Value | 1.20B | 971.91M | 451.08M | 130.79M | 141.26M |
| EV to EBITDA | -7.19 | 116.19 | -6.69 | -3.72 | -7.34 |
| EV to Sales | 14.28 | 10.90 | 15036.10 | 99.38 | 25.66 |
| EV to Free Cash Flow | -7.03 | 74.85 | -7.59 | -3.25 | -8.02 |
| EV to Operating Cash Flow | -7.04 | 71.74 | -7.61 | -3.26 | -8.04 |
| Tangible Book Value Per Share | 1.01 | 2.57 | 2.42 | 6.83 | -1.08 |
| Shareholders’ Equity Per Share | 1.16 | 2.65 | 2.42 | 6.83 | -1.08 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.86 | 0.92 | 0.00 | 0.03 | 0.19 |
| Net Income Per Share | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
| Tax Burden | 1.00 | 0.97 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.02 | 1.00 | 0.81 | 0.98 | 1.04 |
| Research & Development to Revenue | 0.16 | 0.22 | 675.53 | 13.96 | 3.68 |
| SG&A to Revenue | 2.73 | 0.00 | 1576.13 | 14.02 | 0.85 |
| Stock-Based Compensation to Revenue | 0.26 | 0.16 | 307.83 | 4.44 | 0.51 |
| Income Quality | 1.00 | 1.69 | 1.09 | 1.16 | 0.87 |
Currency in USD
